In Brief

Senate backs pre-tax OTC purchases; infirst Healthcare lands $38M investment; Star Scientific faces fraud allegation; Vitamin Shoppe franchise opens in Panama.

The Senate’s fiscal 2014 budget resolution includes an amendment in support of restoring consumers’ ability to purchase OTC drugs with tax-advantaged spending accounts. Amendment 624, proposed by Sen. Mike Johanns, R-Neb., was agreed to by voice vote March 23 during a marathon session in which the Senate approved the budget resolution in a 50-49 vote. The measure was previously introduced in legislation by Johanns and Rep. Erik Paulsen, R-Minn., to roll back the Patient Protection and Affordable Care Act requirement that consumers get a prescription before being eligible to purchase OTCs with a flexible spending or health savings account. Though the budget resolution sets priorities for federal spending and does not establish appropriation levels, the acceptance of Johanns’ amendment “sent a strong bipartisan message that there is support for improvements to the ACA that enhance cost efficiency in the health care system and respect consumer decisions,” said John Gay, VP of government affairs for the Consumer Healthcare Products Association. Previous legislative attempts to restore pre-tax OTC purchases have stalled Also see "Supreme Court Routes OTC Health Savings Battle Back To Congress" - Pink Sheet, 2 July, 2012..

Consumer health care product developer infirst Healthcare secures an investment of about $38 million (£25 million) to help fund the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

340B Rebate Model Gets HRSA Endorsement; Pilot Program Limited To Medicare Negotiated Drugs

 
• By 

Pilot is harbinger of greater transparency in the 340B program. But rebates may only be denied by manufacturers for overlap with Medicare negotiated prices, not for issues like diversion that have driven recent lawsuits.

Double Duty At US FDA: Tidmarsh Will Temporarily Lead Both CDER And CBER

 

Just a week and a half into his tenure at the agency, the new CDER Director George Tidmarsh was also tapped to serve as acting head of CBER. Prasad’s swift ouster at CBER may point to a softening in cell and gene therapy regulation but could also portend even more scrutiny on vaccines.

Big PBM Dominance Enabled By Affiliated Third Party Administrators Limiting Choices, FTC Told

 
• By 

Complaints about TPAs offer an explanation of why self-funded employers continue to use the big three PBMs despite concerns about those relationships. Proposed solutions include banning retaliatory fees and data withholding.

More from North America

Big PBM Dominance Enabled By Affiliated Third Party Administrators Limiting Choices, FTC Told

 
• By 

Complaints about TPAs offer an explanation of why self-funded employers continue to use the big three PBMs despite concerns about those relationships. Proposed solutions include banning retaliatory fees and data withholding.

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

 
• By 

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.

NDA User Fees Will Grow 8.6% Next Year As FDA Projects More Applications But Fewer Sponsor Meetings

 

The ups – and some downs – of the US FDA’s prescription, biosimilar, and generic user fees for FY 2026 are tabulated by the Pink Sheet.